Development of miR-143-lipid nanoparticle-based therapy against KRAS-mutant multiple myeloma

2021 Fiscal Year Final Research Report

• Project/Area Number: 20K16216
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 49030:Experimental pathology-related
• Research Institution: Gifu University
• Principal Investigator: Heishima Kazuki 岐阜大学, 高等研究院, 特任助教 (50826633)
• Project Period (FY): 2020-04-01 – 2022-03-31
• Keywords: 多発性骨髄腫 / マウスモデル

Outline of Final Research Achievements

Effective treatments for KRAS-mutant multiple myeloma are limited. The present study evaluated the antitumor potential of chemically modified microRNA-143 (CM-miR-143), which regulates the entire RAS molecular network by RNA interference, in a KRAS-mutant multiple myeloma mouse model. The result showed that administration of CM-miR-143 significantly reduced the amount of tumor cells distributed in the spleen, as well as the expression of the miR-143 target gene ERK1/2 and the proliferation marker p-Histone H3. On the other hand, no significant antitumor effect was observed in tumor cells distributed to the bone marrow. These findings demonstrated that CM-miR-143 induced significant antitumor effects in a multiple myeloma model, although it has organ specificity.

Free Research Field

腫瘍生物学

Academic Significance and Societal Importance of the Research Achievements

現在、KRAS変異多発性骨髄腫に対しては有効な治療法が限られている。今回の研究によって、KRAS変異多発性骨髄腫に対する、miR-143を使用した核酸医薬の有効性と特徴を明らかにした。